The stock of Delcath Systems, Inc. (NASDAQ:DCTH) reached all time low today, Sep, 30 and still has $2.18 target or 14.00% below today’s $2.54 share price. This indicates more downside for the $3.72 million company. This technical setup was reported by Barchart.com. If the $2.18 PT is reached, the company will be worth $520,800 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 311,391 shares traded hands or 2205.92% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 20.14% since February 26, 2016 and is downtrending. It has underperformed by 30.56% the S&P500.
Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.30, from 1.43 in 2016Q1. The ratio worsened, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Creative Planning has 307 shares for 0% of their US portfolio. Vanguard Gru has 77,988 shares for 0% of their US portfolio. Wells Fargo Mn has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Retail Bank Of America Corporation De accumulated 0% or 4,604 shares. Ladenburg Thalmann Fincl Services holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 1,456 shares. Barclays Public Ltd Liability Company has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Blackrock Institutional Trust Na last reported 531,871 shares in the company. Private Advisor Grp Ltd holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 206,670 shares. Susquehanna Grp Incorporated Limited Liability Partnership last reported 39,047 shares in the company. Royal Commercial Bank Of Canada holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 2,563 shares. Geode Capital Mgmt Limited Liability Corp has 39,792 shares for 0% of their US portfolio. Goldman Sachs accumulated 15,211 shares or 0% of the stock. Moreover, Renaissance has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 754,998 shares. Kcg Hldgs has 0% invested in the company for 12,403 shares. Blackrock Fund Advsrs has 4,024 shares for 0% of their US portfolio.
More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Prnewswire.com which released: “Delcath Announces Proposed Public Offering of Common Stock and Warrants” on September 29, 2016, also Seekingalpha.com with their article: “Delcath prices stock offering at $3; shares off 21%” published on September 30, 2016, Marketwatch.com published: “Delcath Systems Inc.” on December 22, 2009. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Benzinga.com and their article: “Mid-Morning Market Update: Markets Open Higher; McCormick Profit Tops Estimates” published on September 30, 2016 as well as Prnewswire.com‘s news article titled: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” with publication date: September 19, 2016.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.